These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 28038708)

  • 21. BAP1 Immunostain and CDKN2A (p16) FISH Analysis: Clinical Applicability for the Diagnosis of Malignant Mesothelioma in Effusions.
    Walts AE; Hiroshima K; McGregor SM; Wu D; Husain AN; Marchevsky AM
    Diagn Cytopathol; 2016 Jul; 44(7):599-606. PubMed ID: 27121152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Challenges and limitation of MTAP immunohistochemistry in diagnosing desmoplastic mesothelioma/sarcomatoid pleural mesothelioma with desmoplastic features.
    Sa-Ngiamwibool P; Hamasaki M; Kinoshita Y; Matsumoto S; Sato A; Tsujimura T; Kasai T; Hiroshima K; Kushitani K; Takeshima Y; Kawahara K; Iwasaki A; Nabeshima K
    Ann Diagn Pathol; 2022 Oct; 60():152004. PubMed ID: 35797798
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?
    Churg A; Sheffield BS; Galateau-Salle F
    Arch Pathol Lab Med; 2016 Apr; 140(4):318-21. PubMed ID: 26288396
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of p16/cdkn2a loss in pleural malignant mesotheliomas.
    Dacic S; Kothmaier H; Land S; Shuai Y; Halbwedl I; Morbini P; Murer B; Comin C; Galateau-Salle F; Demirag F; Zeren H; Attanoos R; Gibbs A; Cagle P; Popper H
    Virchows Arch; 2008 Dec; 453(6):627-35. PubMed ID: 18958493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genomic Deletion of
    Sarun KH; Lee K; Williams M; Wright CM; Clarke CJ; Cheng NC; Takahashi K; Cheng YY
    Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30301262
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update of pathological diagnosis of pleural mesothelioma using genomic-based morphological techniques, for both histological and cytological investigations.
    Nabeshima K; Hamasaki M; Kinoshita Y; Matsumoto S; Sa-Ngiamwibool P
    Pathol Int; 2022 Aug; 72(8):389-401. PubMed ID: 35596704
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Combination of MTAP and p16 Immunohistochemistry Can Substitute for CDKN2A Fluorescence In Situ Hybridization in Diagnosis and Prognosis of Pleural Mesotheliomas.
    Brcic L; Le Stang N; Gallob F; Pissaloux D; Sequeiros R; Paindavoine S; Pairon JC; Karanian M; Dacic S; Girard N; Churg A; Tirode F; Galateau-Salle F
    Arch Pathol Lab Med; 2023 Mar; 147(3):313-322. PubMed ID: 35738002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BAP1 loss is unusual in well-differentiated papillary mesothelioma and may predict development of malignant mesothelioma.
    Lee HE; Molina JR; Sukov WR; Roden AC; Yi ES
    Hum Pathol; 2018 Sep; 79():168-176. PubMed ID: 29763720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential Diagnosis of Malignant Pleural Mesothelioma on Cytology: A Gene Expression Panel versus BRCA1-Associated Protein 1 and p16 Tests.
    Bruno R; Alì G; Poma AM; Proietti A; Libener R; Mariani N; Niccoli C; Chella A; Ribechini A; Grosso F; Fontanini G
    J Mol Diagn; 2020 Apr; 22(4):457-466. PubMed ID: 32036091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations.
    Sheffield BS; Hwang HC; Lee AF; Thompson K; Rodriguez S; Tse CH; Gown AM; Churg A
    Am J Surg Pathol; 2015 Jul; 39(7):977-82. PubMed ID: 25634745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma.
    McGregor SM; Dunning R; Hyjek E; Vigneswaran W; Husain AN; Krausz T
    Hum Pathol; 2015 Nov; 46(11):1670-8. PubMed ID: 26376834
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis.
    Kinoshita Y; Hamasaki M; Yoshimura M; Matsumoto S; Sato A; Tsujimura T; Ueda H; Makihata S; Kato F; Iwasaki A; Nabeshima K
    Lung Cancer; 2018 Nov; 125():198-204. PubMed ID: 30429020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular characterization of localized pleural mesothelioma.
    Hung YP; Dong F; Dubuc AM; Dal Cin P; Bueno R; Chirieac LR
    Mod Pathol; 2020 Feb; 33(2):271-280. PubMed ID: 31371807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The potential utility of GATA binding protein 3 for diagnosis of malignant pleural mesotheliomas.
    Prabhakaran S; Hocking A; Kim C; Hussey M; Klebe S
    Hum Pathol; 2020 Nov; 105():1-8. PubMed ID: 32888937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pleural mesothelioma classification update.
    Beasley MB; Galateau-Salle F; Dacic S
    Virchows Arch; 2021 Jan; 478(1):59-72. PubMed ID: 33475835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular Characterization of Mesothelioma: Impact of Histologic Type and Site of Origin on Molecular Landscape.
    Dagogo-Jack I; Madison RW; Lennerz JK; Chen KT; Hopkins JF; Schrock AB; Ritterhouse LL; Lester A; Wharton KA; Mino-Kenudson M; Danziger N; Hung YP; Mata DA; Ross JS
    JCO Precis Oncol; 2022 Jun; 6():e2100422. PubMed ID: 35704798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The value of BRCA-1-associated protein 1 expression and cyclin-dependent kinase inhibitor 2A deletion to distinguish peritoneal malignant mesothelioma from peritoneal location of carcinoma in effusion cytology specimens.
    Althakfi W; Gazzo S; Blanchet M; Isaac S; Piaton E; Villeneuve L; Glehen O; Gilly FN; Brevet M
    Cytopathology; 2020 Jan; 31(1):5-11. PubMed ID: 31713897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The significance of BAP1 and MTAP/CDKN2A expression in well-differentiated papillary mesothelial tumour: a series of 21 cases and a review of the literature.
    Hassan A; Prabhakaran S; Pulford E; Hocking AJ; Godbolt D; Ziad F; Pandita A; Wessels A; Hussey M; Russell PA; Klebe S
    Pathology; 2024 Aug; 56(5):662-670. PubMed ID: 38789301
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The importance of FISH signal cut-off values for 9p21 deletion in malignant pleural mesothelioma: Is it underestimated?
    Kulduk G; Ekinci Ö; Toker G; Demirci U; Özaydın E; Akyürek N; Memiş L
    Pathol Res Pract; 2019 Jun; 215(6):152377. PubMed ID: 30885529
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.
    Illei PB; Rusch VW; Zakowski MF; Ladanyi M
    Clin Cancer Res; 2003 Jun; 9(6):2108-13. PubMed ID: 12796375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.